The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2022 | AI in lung cancer screening: accuracy and predictive value
Ricardo Sales Santos, MD, PhD, Hospital Israelita Albert Einstein, São Paulo, Brazil, shares the accuracy and predictive value of an algorithm utilized in lung cancer screening. The algorithm analyzes 709 images from the First Brazilian Lung Cancer Screening (BRELT1) in Brazil. The algorithm showed high sensitivity and predictive value of 97.8% and specificity and positive predictive value of 56.1%, with an overall accuracy of 81.1%. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
